New Delhi, March 31 -- Alzheimer's disease is usually associated with old age. But around 5 per cent-10 per cent of all Alzheimer's cases occur in people under the age of 65. Early-onset Alzheimer's disease progresses more rapidly and often strikes people in the prime of their lives. Treatment options remain limited.

But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, could help. The study found that gantenerumab reduced the buildup of amyloid plaques - one of the hallmarks of Alzheimer's disease - in the brain. This may help slow cognitive decline in people with early-onset Alzheimer's.

Early-onset Alzheimer's is often linked to genetic mutations in three specific ge...